Skip to main content
FEBRUARY 4, 2021
Around one in three working-age adults (29%) surveyed in France in July 2020 would refuse any COVID-19 vaccine fond a team of researcher including Stéphane Luchini (CNRS, AMSE). This study was published in The Lancet Public Health the 5th February 2021.

"Researchers found that more than two-thirds of people (71%) could accept a vaccine depending on its characteristics, with their decision based largely on its effectiveness and country of origin.

Based on their findings, the authors recommend that mass vaccination strategies in France would be most successful if they use vaccines with robust evidence of high levels of effectiveness, especially vaccines produced in the USA or the European Union, and emphasise the collective benefits of herd immunity.

While the study was conducted in France - where vaccine skepticism, in general, is high -highlights potential hurdles that widespread distrust of new vaccines could pose to a vaccine rollout strategy to achieve herd immunity. The authors also note that the study was undertaken before the development of highly effective vaccines, which may have altered people's attitudes."

► More information 

 

Reference :

Read the paper (open access) : Michaël Schwarzinger M., Watson V., Arwidson P., Alla F., Luchini S., 2021, "COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics", The Lancet Public Health, online

 

Contact : 

 Stéphane Luchini (CNRS, AMSE)

 

Latest publications

Toward an Agency for Ecological Transition
Interview with Alain Trannoy (EHESS, AMSE) with Esprit review.
When France’s Légion d’honneur awards move stock prices: A market signal of political access
Two articles by Stéphane Benveniste (University of Paris 1, CES, AMSE) and Marc Sangnier (Aix-Marseille University, AMSE) published in VoxEU (CEPR) and The Conversation.
The 'Dialogues économiques' magazine No. 6 is online
This issue compiles the 'Dialogues économiques' articles published in 2025.